PM David Cameron opens e-Therapeutics’ drug discovery centre

Network Pharmacology Centre will search for novel treatments for cancer and CNS diseases

UK drug discovery and development firm e-Therapeutics has opened a new drug discovery centre at Long Hanborough, near Oxford.

The Network Pharmacology Centre will focus on searching for novel treatments for cancer and degenerative diseases of the nervous system.

UK Prime Minister David Cameron officially opened the centre.

He said: ‘e-Therapeutics is a fascinating and innovative business in my constituency. Their use of pioneering science has the potential to deliver great results and I very much hope that their treatments are successful.’

Professor Malcolm Young, founder and chief executive of e-Therapeutics, added: ‘We are delighted to have the Prime Minister open our new drug discovery centre near Oxford, which is a world centre of excellence in the science that underpins our business.’

The new centre will spearhead e-Therapeutics’ pioneering work in network pharmacology, which involves application of network analysis to determine the set of proteins most critical in any disease, and then chemical biology to identify molecules capable of targeting that set of proteins.

The firm says by addressing the true complexity of disease and by seeking to harness the ability of drugs to influence many different proteins, network pharmacology differs from conventional drug discovery approaches, which have generally been based on highly specific targeting of a single protein.

During 2012, e-Therapeutics plans to advance four drugs derived from network pharmacology research into clinical trials. These include potential treatments for cancer, major depressive disorder and resistant bacterial infections.

The firm’s headquarters are in Newcastle-upon-Tyne.

You may also like

Ingredients

e-therapeutics launches anti-viral drug discovery initiative for COVID-19

UK-based e-therapeutics discusses the moral responsibility of business and reaches out for aid with a network-driven drug discovery platform to help the current pandemic
Research & Development

Could machine learning present a paradigm shift in drug discovery?

Angharad Baldwin catches up with Dr Raymond Barlow, CEO at e-therapeutics, about what network-driven drug discovery can offer the pharmaceutical industry in its pursuit of new medicines
Research & Development

Collaboration to enhance and extend AI technology capabilities

e-Therapeutics, a company pioneering the use of network-driven drug discovery (NDD) to create new and better drugs, announced agreements with Intellegens and Biorelate to develop artificial intelligence (AI) technology capabilities
Research & Development

Quotient Sciences extends partnership for ultra-rare disease treatment

This collaboration reinforces Quotient Sciences’ commitment to supporting the manufacture of niche and smaller volume commercial products often overlooked by larger CDMOs
Research & Development

OSE Immunotherapeutics receives positive IDMC review for Phase III ARTEMIA trial

OSE Immunotherapeutics SA has received a second positive recommendation from the Independent Data Monitoring Committee to continue its Phase III ARTEMIA trial of Tedopi in advanced non-small cell lung cancer
Research & Development

Vilnius University scientists reveal new role for CRISPR-Cas9 in bacterial immunity

The researchers report in Molecular Cell that the CRISPR-Cas9 protein plays a previously unknown role in selecting and integrating viral DNA fragments during bacterial immune memory formation
Research & Development

Lilly’s Orforglipron beats oral semaglutide in Phase III ACHIEVE-3 trial with superior weight loss

Head-to-head data published in The Lancet show Eli Lilly's oral GLP-1 candidate orforglipron delivered significantly greater HbA1c reductions and weight loss than oral semaglutide in adults with type 2 diabetes, supporting global regulatory submissions
Subscribe now